Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 4/20 | 0.75 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583348 | 1.00 | CTSC (0.75) | CTSCMMP2NPC1RAB9AALPI | |
| SCHEMBL13858664 | 1.00 | CTSC (0.75) | CTSCMMP2NPC1RAB9AALPI | |
| SCHEMBL11863638 | 0.90 | CTSC (0.62) | CTSCMMP2NPC1RAB9AAOC3 | |
| SCHEMBL11863650 | 0.90 | CTSC (0.62) | CTSCMMP2NPC1RAB9AAOC3 | |
| SCHEMBL27899225 | 0.86 | CTSC (0.56) | CTSCSLC7A5 | |
| SCHEMBL27698308 | 0.84 | CTSC (0.54) | CTSCNPC1RAB9AMMEALDH1A1 | |
| SCHEMBL9871281 | 0.84 | ALDH1A1 (0.60) | CTSCNPC1RAB9AMMEALDH1A1 | |
| SCHEMBL4093741 | 0.84 | CTSC (0.55) | CTSCPKMHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL2911850 | 0.83 | CTSC (0.53) | CTSCNPC1RAB9AALPIPKM | |
| SCHEMBL2911851 | 0.83 | CTSC (0.53) | CTSCNPC1RAB9AALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669229-B2 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-11 | — | — | US | claimed |
| CN-103342680-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2013-10-09 | — | — | CN | claimed |
| EP-2170831-B1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 2012-02-15 | — | — | EP | claimed |
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | US | claimed |
| EP-2170831-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | claimed |
| CN-101687805-A | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD | 2010-03-31 | — | — | CN | claimed |
| WO-2009001968-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-31 | — | — | WO | claimed |
| CN-1658819-A | Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form | OREAL (FR) | 2005-08-24 | — | — | CN | claimed |
| EP-1515684-A2 | CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM | L'OREAL (FR) | 2005-03-23 | — | — | EP | claimed |
| WO-2003105788-A2 | CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM | L'OREAL (FR) | 2003-12-24 | — | — | WO | claimed |
| EP-1363656-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | Neurotell AG (CH) | 2003-11-26 | — | — | EP | claimed |
| EP-1359934-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Neurotell AG (CH) | 2003-11-12 | — | — | EP | claimed |
| WO-2002062828-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| WO-2002062373-A2 | TRIPEPTIDES AND TRIPEPTIDE DERIVATIVES FOR THE TREATMENT OF POSTLESIONAL DISEASES OF THE NERVOUS SYSTEM | NEUROTELL AG (CH) | 2002-08-15 | — | — | WO | claimed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | claimed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | claimed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | claimed |
| US-9896711-B2 | Fluorogenic or fluorophoric compounds and uses thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
| CN-85101902-A | Enkephalinase inhibitor | — | 1987-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1B, AVPR1A | CTSC 863/4885MMP2 2501/4885NPC1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.